Cargando…

Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies

Adjuvant endocrine therapy improves the prognosis of early breast cancer with hormone receptor positivity. However, there is no systematic report on the effect of endocrine therapy (particularly ovarian function suppression, OFS) on serum lipids in premenopausal women. This retrospective cohort stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kaiyue, Shen, Lu, Tian, Wei, Zhang, Suzhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805421/
https://www.ncbi.nlm.nih.gov/pubmed/36587111
http://dx.doi.org/10.1038/s41598-022-27008-x
_version_ 1784862334154440704
author Wang, Kaiyue
Shen, Lu
Tian, Wei
Zhang, Suzhan
author_facet Wang, Kaiyue
Shen, Lu
Tian, Wei
Zhang, Suzhan
author_sort Wang, Kaiyue
collection PubMed
description Adjuvant endocrine therapy improves the prognosis of early breast cancer with hormone receptor positivity. However, there is no systematic report on the effect of endocrine therapy (particularly ovarian function suppression, OFS) on serum lipids in premenopausal women. This retrospective cohort study aimed to determine whether various endocrine treatments had different effects on blood lipids. This study enrolled 160 premenopausal patients with stage I–III breast cancer in eastern China. The initial diagnostic information was retrieved from patient's medical records, including age at the time of diagnosis, tumor characteristics, anticancer treatment and past medical history. The changes in blood lipids in patients receiving different types of endocrine therapy were compared at the 3rd, 6th, 12th, and 24th months after initiating endocrine therapy. Generalized linear mixed model was used in our analyses. Our data revealed that low-density lipoprotein cholesterol (LDL-C) levels in patients with tamoxifen (TAM) were significantly lower in the 6th, 12th, and 24th months than that in the 3rd month, while high-density lipoprotein cholesterol (HDL-C) levels in the 6th, 12th, and 24th months were significantly higher than that in the 3rd month, indicating that blood lipid levels generally improved with time. While in TAM plus OFS group, HDL-C levels were significantly higher in the 24th month than in the 3rd month, total cholesterol (TC) levels were significantly higher in the 24th month than in the 6th month. The lipid profiles of OFS plus aromatase inhibitor (AI) group did not show significant differences at any time point but were significantly higher than those of the other two groups especially in LDL and TC. TAM group tended to have lower serum lipid levels. With longer follow-up, no statistically significant difference in values was observed between TAM and TAM plus OFS groups at various time points. Compared with the other two groups, OFS plus AI group presented an increasing trend toward LDL-C and TC. The risk of dyslipidemia requires further investigation using a large sample size.
format Online
Article
Text
id pubmed-9805421
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98054212023-01-02 Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies Wang, Kaiyue Shen, Lu Tian, Wei Zhang, Suzhan Sci Rep Article Adjuvant endocrine therapy improves the prognosis of early breast cancer with hormone receptor positivity. However, there is no systematic report on the effect of endocrine therapy (particularly ovarian function suppression, OFS) on serum lipids in premenopausal women. This retrospective cohort study aimed to determine whether various endocrine treatments had different effects on blood lipids. This study enrolled 160 premenopausal patients with stage I–III breast cancer in eastern China. The initial diagnostic information was retrieved from patient's medical records, including age at the time of diagnosis, tumor characteristics, anticancer treatment and past medical history. The changes in blood lipids in patients receiving different types of endocrine therapy were compared at the 3rd, 6th, 12th, and 24th months after initiating endocrine therapy. Generalized linear mixed model was used in our analyses. Our data revealed that low-density lipoprotein cholesterol (LDL-C) levels in patients with tamoxifen (TAM) were significantly lower in the 6th, 12th, and 24th months than that in the 3rd month, while high-density lipoprotein cholesterol (HDL-C) levels in the 6th, 12th, and 24th months were significantly higher than that in the 3rd month, indicating that blood lipid levels generally improved with time. While in TAM plus OFS group, HDL-C levels were significantly higher in the 24th month than in the 3rd month, total cholesterol (TC) levels were significantly higher in the 24th month than in the 6th month. The lipid profiles of OFS plus aromatase inhibitor (AI) group did not show significant differences at any time point but were significantly higher than those of the other two groups especially in LDL and TC. TAM group tended to have lower serum lipid levels. With longer follow-up, no statistically significant difference in values was observed between TAM and TAM plus OFS groups at various time points. Compared with the other two groups, OFS plus AI group presented an increasing trend toward LDL-C and TC. The risk of dyslipidemia requires further investigation using a large sample size. Nature Publishing Group UK 2022-12-31 /pmc/articles/PMC9805421/ /pubmed/36587111 http://dx.doi.org/10.1038/s41598-022-27008-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wang, Kaiyue
Shen, Lu
Tian, Wei
Zhang, Suzhan
Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
title Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
title_full Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
title_fullStr Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
title_full_unstemmed Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
title_short Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
title_sort comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805421/
https://www.ncbi.nlm.nih.gov/pubmed/36587111
http://dx.doi.org/10.1038/s41598-022-27008-x
work_keys_str_mv AT wangkaiyue comparisonofchangesinlipidprofilesofpremenopausalwomenwithearlystagebreastcancertreatedwithdifferentendocrinetherapies
AT shenlu comparisonofchangesinlipidprofilesofpremenopausalwomenwithearlystagebreastcancertreatedwithdifferentendocrinetherapies
AT tianwei comparisonofchangesinlipidprofilesofpremenopausalwomenwithearlystagebreastcancertreatedwithdifferentendocrinetherapies
AT zhangsuzhan comparisonofchangesinlipidprofilesofpremenopausalwomenwithearlystagebreastcancertreatedwithdifferentendocrinetherapies